Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With Lu-177-PSMA-617

摘要

An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-177-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expression in Ga-68-PSMA PET performed before the first cycle. Under this therapy, all of the metastases showed significant regression in size and PSMA expression over time.